scispace - formally typeset
J

José M. Rayón

Publications -  17
Citations -  2888

José M. Rayón is an academic researcher. The author has contributed to research in topics: Liver transplantation & Cirrhosis. The author has an hindex of 13, co-authored 17 publications receiving 2848 citations.

Papers
More filters
Journal ArticleDOI

Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients.

TL;DR: In this paper, the authors describe the natural history of HCV-infected recipients, particularly to determine whether survival has decreased in recent years, and compare this outcome with that observed in non-HCVinfected cirrhosis controls.
Journal ArticleDOI

Natural History of Clinically Compensated Hepatitis C Virus–Related Graft Cirrhosis After Liver Transplantation

TL;DR: The natural history of clinically compensated HCV‐graft cirrhosis is shortened when compared with immunocompetent patients, and if retransplantation is considered, it should be performed promptly once decompensation develops.
Journal ArticleDOI

High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: Relationship with rejection episodes

TL;DR: HCV genotype 1b–infected liver recipients are at a high risk of developing graft cirrhosis in the first 4 to 5 years following transplantation, especially those with previous rejection episodes.
Journal ArticleDOI

Contribution of obesity to hepatitis C-related fibrosis progression.

TL;DR: Obesity, advanced age at infection, and elevated ALT levels predict rapid disease progression, suggesting that measures aimed at weight reduction may play a significant role in hepatitis C management.
Journal ArticleDOI

De novo hepatitis B after liver transplantation from hepatitis B core antibody—Positive donors in an area with high prevalence of anti-HBc positivity in the donor population

TL;DR: The aims of this study are to assess the risk for de novo hepatitis B in recipients of livers from anti‐ HBc+ donors in an area of high prevalence of anti‐HBc positivity in the donor population, and to analyze the risk factors for acquisition of HBV infection from anti-HBc + donors.